register

News & Trends - Pharmaceuticals

Novel drug delivery more effective in bowel cancer

Health Industry Hub | May 5, 2021 |

Pharma News: Bowel cancer survival rates could be improved if chemotherapy drugs were delivered via tiny nanoparticles to the diseased organs rather than oral treatment.

That’s the finding from Indian and Australian scientists who have undertaken the first study, using nanoparticles to target bowel cancer, the third most common cancer in the world and the second most deadliest.

The researchers have shown in animal experiments that nanoparticles containing Roche’s chemotherapy drug Xeloda (capecitabine) attach themselves directly to the diseased cells, bypassing healthy cells and therefore reducing toxic side effects as well as the size and number of tumours.

The scientists, from the University of South Australia, the Manipal Academy of Higher Education and Indian Institute of Science have published their findings in the journal Carbohydrate Polymers.

UniSA Professor of Pharmaceutical Science, Sanjay Garg – the sole Australian researcher involved in the project – says that Xeloda is the first-line chemotherapy drug for bowel cancer. He co-supervised the PhD scholar Reema Narayan, with Prof Usha Nayak from Manipal, India.

“Due to its short life, a high dose is necessary to maintain effective concentration, resulting in some harsh side effects when delivered conventionally, including severe hand and foot pain, dermatitis, nausea, vomiting, dizziness and loss of taste,” Prof Garg says.

The side effects are exacerbated because the drug affects both healthy and diseased cells.

“A viable alternative to conventional therapy is targeted drug delivery using nanoparticles as smart carriers so that the drug can be delivered specifically to the tumour. This allows a smaller and less toxic dose,” he says.

CAP delivered via nanoparticles reduces both the size and number of cancerous bowel tumours, results in fewer abnormal cells, improved red and white blood cell counts and less damage to other organs.

The targeted delivery system has a dual function: binding the receptors as well as releasing the drug to the tumour micro-environment.

“It has been a challenging project but we believe the platform technology developed can be applied to other cancers and chemotherapeutic drugs,” Prof Garg says.

Approximately two million people are diagnosed with bowel cancer each year and half of those are not expected to survive, according to the World Health Organisation.


News & Trends - Biotechnology

AusBiotech appoints new CEO: Former Sanofi corporate affairs and sustainability leader takes the helm

AusBiotech appoints new CEO: Former Sanofi corporate affairs and sustainability leader takes the helm

Health Industry Hub | April 23, 2024 |

Biotech News: AusBiotech, the nation’s leading industry body for the biotech sector, has named former leader at Sanofi, Rebekah Cassidy, […]

More


News & Trends - MedTech & Diagnostics

Federal government invests in Siemens Healthineers scanner to 'reduce wait times' for cancer diagnosis

Federal government invests in Siemens Healthineers scanner to ‘reduce wait times’ for cancer diagnosis

Health Industry Hub | April 23, 2024 |

MedTech & Diagnostics News: The Albanese Government is investing $12 million through the 2024–25 Budget, to purchase and install a […]

More


News & Trends - MedTech & Diagnostics

Cardiac device benefits face more cuts, while technical services remain secure in the short term

Cardiac device benefits face more cuts, while technical services remain secure in the short term

Health Industry Hub | April 23, 2024 |

MedTech & Diagnostics News: Starting from July 2024, Cardiac Implantable Electronic Devices (CIED) listed on the Prescribed List (PL) will […]

More


News & Trends - Biotechnology

CSL's world-first gene therapy heads for MSAC assessment

CSL’s world-first gene therapy heads for MSAC evaluation

Health Industry Hub | April 23, 2024 |

Biotech News: CSL’s world-first gene therapy for haemophilia B is scheduled for consideration at the upcoming Medical Services Advisory Committee (MSAC) […]

More


This content is copyright protected. Please subscribe to gain access.